Catastrophic relapse of Evans syndrome five years after allogeneic BMT notwithstanding full donor chimerism. Terminal hemolytic-uremic syndrome

References

• Savasan S, Warner I, Ravindravath Y. The spectrum of Evans syndrome. Arch Dis Child 1997; 77: 245–248
   PubMed Web of Science ®Google Scholar
• Ng SC. Evans syndrome: A report on 12 patients. Clin Lab Haematol 1992; 14: 189–193
   PubMedGoogle Scholar
• Mathew P, Chen G, Wang W. Evans syndrome: Results of a national survey. J Pediatr Hematol/Oncol 1997; 19: 423–437
   Google Scholar
• Teachey DT, Manno CS, Axsom KM, et al. Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS). Blood 2005; 105: 2443–2448
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Petri M, Smith BD, et al. Immunoablative high dose cyclophosphamide without stem cell rescue for refractory severe autoimmune diseases. Ann Intern Med 1998; 129: 1031–1035
   PubMed Web of Science ®Google Scholar
• Huhn RD, Fogarty P, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 2003; 101: 71–77
   PubMed Web of Science ®Google Scholar
• Passweg J, Rabusin M, Musso M, for the Autoimmune Disease Working Party of the European Group for Blood and Marrow Transplantation, et al. Hematopoietic stem cell transplantation for refractory autoimmune cytopenia. Br J Haematol 2004; 125: 749–755
   PubMed Web of Science ®Google Scholar
• Raetz E, Beatty PG, Adams RH. Treatment of severe Evans syndrome with an allogeneic cord blood transplant. Bone Marrow Transplant 1997; 20: 427–429
   PubMed Web of Science ®Google Scholar
• Oyama Y, Papadopoulos EB, Miranda M, et al. Allogeneic stem cell transplantation for Evans syndrome. Bone Marrow Transplant 2001; 28: 903–905
   PubMed Web of Science ®Google Scholar
• Marmont AM, Gualandi F, van Lint MT, Bacigalupo A. Refractory Evans syndrome treated with allogeneic SCT followed by DLI. Demonstration of a graft-versus-autoimmunity effect. Bone Marrow Transplant 2003; 31: 399–402
   PubMed Web of Science ®Google Scholar
• Traggiai E, Becker S, Subbarao S, et al. An efficient method to make monoclonal antibodies from memory B cells: Potent neutralization of SARS. Nat Med 2004; 10: 871–875
   PubMed Web of Science ®Google Scholar
• Griffiths LM, Pavletic SZ, Tyndall A, et al. Feasibility of allogeneic hematopoietic stem cell transplantation for autoimmune disease: Position statement from a National Institute of Allergy and Infections Diseases and National Cancer Institute-sponsored International Workshop, Bethesda, MD, March 12 and 13, 2005. Biology of Blood and Marrow Trasnsplantation 2005; 11: 862–870
   Google Scholar
• van Bekkum DW. Preclinical experiments. Best Pract Res Clin Haematol 2004; 17: 201–222
   PubMed Web of Science ®Google Scholar
• Sykes M, Nikolic B. Treatment of severe autoimmune disease by stem cell transplantation. Nature 2005; 435: 620–627
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Varadi G, Or R. Graft vs autoimmunity following allogeneic nonmyeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Exp Hematol 2000; 28: 853–857
   PubMed Web of Science ®Google Scholar
• Marmont AM. Is there any evidence of a graft-versus-autoimmunity effect in allogeneic transplantation?. Blood Marrow Transplant Rev 2004; 4: 11
   Google Scholar
• Hinterberger W, Hinterberger-Fischer M, Marmont AM. Clinically demonstrable anti-autoimmunity mediated by allogeneic immune cells favourably affects outcome after stem cell transplantation in human autoimmune diseases. Bone Marrow Transplant 2002; 30: 753–759
   PubMed Web of Science ®Google Scholar
• Musso M, Porretto F, Crescimanno A, et al. Donor lymphocyte infusions for refractory pure red cell aplasia relapsing after both autologous and allogeneic peripheral stem cell transplantation. Bone Marrow Transplant 2004; 33: 769–771
   PubMedGoogle Scholar
• Hayden PJ, Crampe M, Lawler M, et al. Use of DLI to achieve complete donor chimerism in a patient receiving systemic immunosuppression for refractory AIHA post-NST. Bone Marrow Transplant 2005; 36: 735–736
   PubMedGoogle Scholar
• Chakrabarti S, Handa SK, Bryon J, et al. Will mixed chimerism cure autoimmune diseases after a nonmyeloablative stem cell transplant?. Transplantation 2000; 72: 140–142
   Google Scholar
• Burt RK, Oyama Y, Verda L, et al. Induction of remission of severe and refractory rheumatoid arthritis by allogeneic mixed chimerism. Arthrit Rheum 2004; 50: 2466–2470
   PubMed Web of Science ®Google Scholar
• Khorshid O, Hosing C, Bibawi S, et al. Nonmyeloablative stem cell transplant in a patient with advanced systemic sclerosis and systemic lupus erythematosus. J Rheumatol 2004; 31: 2513–2516
   PubMed Web of Science ®Google Scholar
• Adkins DR, Abidi MM, Brown RA, et al. Resolution of psoriasis after allogeneic bone marrow transplantation for chronic myelogenous leukemia: Late complications of therapy. Bone Marrow Transplant 2000; 26: 1239–1241
   Google Scholar
• Kojima R, Kami M, Kim S-W, et al. Induction of graft-versus autoimmune (GVA) disease effect against refractory psoriasis by complete donor-type chimerism and graft-versus-host disease after allogeneic hematopoietic system cell transplantation. Bone Marrow Transplant 2003; 32: 439–442
   PubMed Web of Science ®Google Scholar
• Seifert B, Passweg JR, Heim D, et al. Complete remission of alopecia universalis after allogeneic stem cell transplantation. Transplantation 2005; 105: 426–427
   Google Scholar
• Antin JH, Childs R, Filipovich AH, et al. Establishment of complete and mixed donor chimerism after allogeneic lymphohematopoietic transplantation: Recommendations from a workshop at the Tandem Meetings of the International Bone Marrow Transplant Registry and the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2001; 7: 473–485
   PubMed Web of Science ®Google Scholar
• Pieroni F, Olivetta FM, Panepucci RA, et al. Development of donor cell derived acute myeloid leukemia after stem cell transplantation for chronic myeloid leukemia. Bone Marrow Transplant 2006; 37: 801–802
   Google Scholar
• Hertenstein B, Hambach L, Bacigalupo A, et al. Development of leukemia in donor cells after allogeneic stem cell transplantation—a survey of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2005; 90: 969–975
   PubMed Web of Science ®Google Scholar
• Marmont AM. Coincidental autoimmune disease in patients transplanted for conventional indications. Best Pract Res Clin Haematol 2004; 17: 201–222
   Google Scholar
• Snowden JA, Kearney P, Kearney A, et al. Long-term outcome of autoimmune diseases following allogeneic bone marrow transplantation. Arthrit Rheum 1998; 41: 453–459
   PubMed Web of Science ®Google Scholar
• McKendry RJ, Huebsch L, Leclair B. Progression of rheumatoid arthritis following bone marrow transplantation. A case report with a 13-year follow-up. Arthrit Rheum 1996; 39: 1246–1253
   PubMed Web of Science ®Google Scholar
• Tapprich C, Feuk R, Schneider P, et al. Early recurrence of rheumatoid arthritis after nonmyeloablative stem cell transplantation in a patient with multiple myeloma. Bone Marrow Transplant 2003; 32: 629–631
   PubMed Web of Science ®Google Scholar
• Manz RA, Hauser AE, Hiepe F, et al. Maintenance of serum antibody levels. Ann Rev Immunol 2005; 23: 367–386
   PubMed Web of Science ®Google Scholar
• Hoyer BE, Manz RA, Radbruch A, Hiepe F. Long-lived plasma cells and their contribution to autoimmunity. Ann NY Acad Sci 2005; 1050: 124–133
   PubMed Web of Science ®Google Scholar
• Hoyer B, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med 2004; 199: 1577–1584
   PubMed Web of Science ®Google Scholar
• Ikehara S. Treatment of autoimmune diseases by hematopoietic stem cell transplantation. Exp Hematol 2001; 29: 661–669
   PubMed Web of Science ®Google Scholar
• Shapiro-Shelef M, Lin KI, Savitsky D, et al. Blimp-1 is required for maintenance of long-lived plasma cells in the bone marrow. J Exp Med 2005; 202: 1471–1476
   PubMedGoogle Scholar
• Gratwohl A, Passweg J, Bocelli-Tyndall C, et al. Autologous hematopoietic stem cell transplantation for autoimmune disease. Bone Marrow Transplant 2005; 35: 869–879
   PubMed Web of Science ®Google Scholar
• Sun W, Popat U, Hutton G, et al. Characteristics of T-cell receptor repertpoire and myelin-reactive T cells reconstituted from autologous hematopoietic stem-cell grafts in multiple sclerosis. Brain 2004; 127: 996–1008
   PubMed Web of Science ®Google Scholar
• Muraro P, Douek DK, packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201: 805–816
   PubMed Web of Science ®Google Scholar
• de Kleer I, Vastert B, Klein M, et al. Autologous stem cell transplantation for autoimmunity induces immunologic self-tolerance by reprogramming autorective T cells and restoring the CD4+ CD25+ immune regulatory network. Blood 2006; 107: 1696–1702
   PubMed Web of Science ®Google Scholar
• Fathman CG, Soares L, Chan SM, Utz PJ. An array of possibilities for the study of autoimmunity. Nature 2005; 435: 605–611
   PubMed Web of Science ®Google Scholar
• George JN, Selby GB. Thrombotic microangiopathy after allogeneic bone marrow transplantation: A pathologic abnormality associated with diverse clinical syndromes. Bone Marrow Transplant 2004; 33: 1073–1074
   Google Scholar
• Daly AS, Xenocostas A, Lipton JH. Transplantation-associated thrombotic microangiopathy: Twenty-two years later. Bone Marrow Transplant 2002; 30: 709–715
   PubMed Web of Science ®Google Scholar
• Caprioli J, Peng L, Remuzzi G:. The hemolytic uremic sindrome. Curr Opin Crit Care 2005; 11: 487–492
   Google Scholar
• De Sanctis LB, Mandreoli M, Poggi C, et al. Acute renal failure in a young woman with Fisher–Evans syndrome. J Nephrol 2004; 17: 739–743
   Google Scholar
• Licht C, Stapenhorst L, Simon T, et al. Two novel ADAMTS 13 gene mutations in thrombotic thrombocytopenic purpura/haemolytic uremic syndrome (TTP/HUS). Kidney Internat 2004; 66: 955
   PubMedGoogle Scholar
• Furlan M, Lammle B. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic-uremic syndrome: The role of von Willebrand factor-cleaving protease. Best Pract Res Clin Haematol 2001; 14: 437–454
   PubMed Web of Science ®Google Scholar
• Rock G, Clark W, Sternbach M, et al. Haemolytic uraemic syndrome is an immune-mediated disease: Role of anti-CD36 antibodies. Br J Haematol 2005; 131: 247–252
   PubMedGoogle Scholar
• Marmont AM. Editorial. Allogeneic haematopoietic stem cell transplantation for severe autoimmune diseases: Great expectations but controversial evidence. Bone Marrow Transplant 2006; 38: 1061–1063
   Google Scholar